Previous close | 657.15 |
Open | 661.29 |
Bid | 645.63 x 800 |
Ask | 662.89 x 800 |
Day's range | 647.54 - 664.85 |
52-week range | 492.13 - 747.42 |
Volume | |
Avg. volume | 646,824 |
Market cap | 71.101B |
Beta (5Y monthly) | 0.21 |
PE ratio (TTM) | 10.57 |
EPS (TTM) | 62.53 |
Earnings date | 03 Feb 2022 - 07 Feb 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 702.05 |
Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog